David D Chang sold $91k of ALLO
President and CEO at Allogene Therapeutics, Inc.. 46,668 shares at an average of $1.96, traded Mar 14, 2025, filed Mar 18, 2025.
Score components
- +25RoleCEO
- +9Trade size$91k at market
- 0Share of holdings soldSold 0.9% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001737287-25-000042, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 14, 2025 | SOpen-market sale Common Stock | -46,668 | $1.96 | $91k | 5,276,569 | Mar 18, 2025 |
Related signals
Other insiders at Allogene Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Allogene Therapeutics, Inc. | Deborah M. Messemer director | $52k 36,885 shares | -26% | |
| 15Weak | ALLOsell Allogene Therapeutics, Inc. | Annie Yoshiyama SVP, Finance | $14k 9,601 shares | -7% | |
| 23Weak | Allogene Therapeutics, Inc. | Benjamin Machinas Beneski SVP, Chief Technical Officer | $11k 5,488 shares | -2% | |
| 0Weak | Allogene Therapeutics, Inc. | Deborah M. Messemer director | $32k 13,313 shares | -8% | |
| 35Weak | Allogene Therapeutics, Inc. | Zachary Roberts EVP of R&D | $32k 18,832 shares | -3% | |
| 48Moderate | Allogene Therapeutics, Inc. | David D Chang President and CEO | $77k 46,003 shares | -1% | |
| 35Weak | Allogene Therapeutics, Inc. | Timothy L. Moore Chief Technical Officer | $25k 14,746 shares | -6% | |
| 37Weak | Allogene Therapeutics, Inc. | Geoffrey M. Parker CHIEF FINANCIAL OFFICER | $7,545 4,361 shares | -0% | |
| 30Weak | Allogene Therapeutics, Inc. | Earl Martin Douglas SVP, General Counsel | $11k 6,404 shares | -1% | |
| 37Weak | Allogene Therapeutics, Inc. | Zachary Roberts EVP of R&D | $48k 27,199 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.